$CRSP CRISPR Therapeutics AG Insider Trading Week 17/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in CRISPR Therapeutics AG in week 17/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 2,206 | 3,993 | 294,558 | |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,275 | 5,928 | 296,764 | |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.78 | 2,206 | 37,023 | 134,047 | 136.3 K to 134 K (-1.62 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 2,206 | 3,993 | 136,253 | 134 K to 136.3 K (+1.65 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.74 | 3,275 | 54,816 | 134,047 | 137.3 K to 134 K (-2.38 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,275 | 5,928 | 137,322 | 134 K to 137.3 K (+2.44 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.62 | 4,912 | 81,638 | 170,056 | 175 K to 170.1 K (-2.81 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.84 | 13,527 | 227,799 | 174,968 | 188.5 K to 175 K (-7.18 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.76 | 3,200 | 53,641 | 180,495 | 183.7 K to 180.5 K (-1.74 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.87 | 4,800 | 80,990 | 183,695 | 188.5 K to 183.7 K (-2.55 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.44 | 3,522 | 57,897 | 188,495 | 192 K to 188.5 K (-1.83 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.02 | 3,010 | 51,222 | 192,017 | 195 K to 192 K (-1.54 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 5,115 | 9,258 | 300,039 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,500 | 6,335 | 305,154 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,000 | 5,430 | 308,654 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.87 | 5,115 | 86,290 | 134,047 | 139.2 K to 134 K (-3.68 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 5,115 | 9,258 | 139,162 | 134 K to 139.2 K (+3.82 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.46 | 3,500 | 57,619 | 134,047 | 137.5 K to 134 K (-2.54 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,500 | 6,335 | 137,547 | 134 K to 137.5 K (+2.61 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.01 | 3,000 | 51,033 | 134,047 | 137 K to 134 K (-2.19 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,000 | 5,430 | 137,047 | 134 K to 137 K (+2.24 %) |